Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle
Vishnu Kumarasamy(Roswell Park Comprehensive Cancer Center), Erik S. Knudsen(Roswell Park Comprehensive Cancer Center)
Cited by 28
Related Papers
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
|Nature Communications|2015|1.1k
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
|Endocrine Related Cancer|2011|299
Dual Mechanisms for the Inhibition of E2F Binding to RB by Cyclin-Dependent Kinase-Mediated RB Phosphorylation
|Molecular and Cellular Biology|1997|290